Company profile: Okogen
1.1 - Company Overview
Company description
- Provider of ophthalmic anti-infective drug candidates, including OKG-0303, a fixed-dose combination eyedrop for acute infectious conjunctivitis that combines an antiviral, ocular decongestant, and antibacterial; OKG-0301, an antiviral shown to inhibit viral replication in adenoviral conjunctivitis; and the RUBY trial evaluating the safety and efficacy of OKG-0301.
Products and services
- OKG-0301: Antiviral-class component of OKG-0303 shown to inhibit viral replication in adenoviral conjunctivitis, serving as the antiviral active within the combination eyedrop
- OKG-0303: Fixed-dose eyedrop combining an antiviral, an ocular decongestant, and an antibacterial to treat acute infectious conjunctivitis as a multi-component therapeutic product
- RUBY Trial: Ophthalmic clinical trial evaluating safety and efficacy of OKG-0301 in patients with adenoviral conjunctivitis, assessing treatment outcomes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Okogen
ProStrakan
HQ: United Kingdom
Website
- Description: Provider of specialty pharmaceutical development and commercialisation of prescription medicines for unmet therapeutic needs in major markets; headquartered in Scotland with more than 300 employees and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProStrakan company profile →
Helix BioMedix
HQ: United States
Website
- Description: Provider of skin health consumer products and bioactive peptide solutions for dermatological and personal care, including a proprietary peptide library with antimicrobial, anti-inflammatory and wound healing properties; SmartPeptides to enhance skin appearance; Oligopeptide-10 for acne; Palmitoyl Hexapeptide-14 and Hexapeptide-21 to stimulate collagen; and HB4208, a preclinical DNA Damage Response enzyme for Xeroderma Pigmentosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helix BioMedix company profile →
Vaxcyte
HQ: United States
Website
- Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxcyte company profile →
Quick-Med Technologies
HQ: United States
Website
- Description: Provider of proprietary, broad-based life sciences technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quick-Med Technologies company profile →
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Okogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Okogen
2.2 - Growth funds investing in similar companies to Okogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Okogen
4.2 - Public trading comparable groups for Okogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →